| ★ | CAPTAIN-T2D: Interim Results Display High Cortisol Prevalence in Difficult-to-Control T2D | | 47 | Estados Unidos | |
| 18 | Inhaled Treprostinil for IPF: TETON-1 Phase 3 Results With Steven Nathan, MD | ATS 2026 | | 301 | Estados Unidos | 61 |
| 16 | New Patch Pump Options Highlighted at ADCES 2026 | | 152 | Estados Unidos | 61 |
| 7 | How Does the FDA Approval of Risankizumab Impact Pediatric Psoriasis and PsA? With Amy Paller, MD | | 109 | Estados Unidos | 63 |
| 2 | Ruxolitinib, Tapinarof, Roflumilast: What's New for Pediatric AD | | 102 | Estados Unidos | 66 |
| 14 | Phase 3b Data on Ixekizumab, Tirzepatide for Psoriasis and Overweight, With Mark Lebwohl, MD | | 88 | Estados Unidos | 62 |
| 15 | SUNRISE: Tezepelumab Shows Meaningful OCS Reduction in Severe Asthma | | 78 | Estados Unidos | 62 |
| 6 | Tezepelumab Cuts Severe Asthma Exacerbations 70% in Real-World Patients | ATS 2026 | | 68 | Estados Unidos | 63 |
| 20 | Hidden Triggers of Perioperative Anaphylaxis: Kimberly Blumenthal, MD, MSc | | 60 | Estados Unidos | 61 |
| 8 | Primary Aldosteronism More Common Than Previously Believed, Requires Increased Screening | | 47 | Estados Unidos | 62 |
| 9 | Mifepristone Improves HbA1c, Weight in Poorly Controlled T2D, Regardless of GLP-1 Treatment | | 46 | Estados Unidos | 62 |
| 3 | POCUS is Standard of Care in Critical Care, With Rhea Votipka, NP | | 35 | Estados Unidos | 65 |
| 13 | Non-Sesame Seed and Spice Allergies Can Trigger Severe Reactions | | 35 | Estados Unidos | 62 |
| 1 | HPA-Axis Assessment Allows for Improved Corticosteroid Response Analysis | | 32 | Estados Unidos | 66 |
| 4 | APPs Uniquely Positioned in ILD Collaborative Care | | 31 | Estados Unidos | 65 |
| 12 | Identifying Confounders in Persistent Hypothyroidism Symptoms, With Rosemarie Lajara, MD | | 29 | Estados Unidos | 62 |
| 17 | ALA: Why COVID-19 Boosters Matter Now, With Juanita Mora, MD | | 28 | Estados Unidos | 61 |
| 11 | Decoding PH Monitoring, Testing, and Referral, With Susanne McDevitt, DNP | | 26 | Estados Unidos | 62 |
| 5 | Health Insurance Largely Controls Financial Toxicity in Patients With T1D | | 20 | Estados Unidos | 63 |
| 10 | Time to Minimum Residual C-Peptide As a Predictor of Treatment Efficacy in T1D | | 16 | Estados Unidos | 62 |